- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zydus Lifesciences Limited — Updates, 11-08-2026: Press Release
11-08-2026 | 06:52 pm
11-08-2026 | 06:52 pm
Zydus' Sentynl unit secured US commercial & global manufacturing rights for alvelestat, a potential first-in-class oral treatment for rare lung disease. Deal with Mereo BioPharma includes an option fee, up to $40 million (~332 Cr) in payments, and US sales royalties.
No comments yet. Be the first to comment!